← Russell 3000 cross-section

EDIT Editas Medicine, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$505m
Revenue TTM
$47m
Net income TTM
$-74m
Free cash flow
$-121m
Composite score
40.1
Sector rank
#2396

Valuation

P / E
EV / EBITDA
EV / sales
7.3
FCF yield
-23.89%
Earnings yield vs 10-yr
-19.38pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-157.3%
EBITDA margin
-156.2%
ROE
-70.2%
ROIC
Revenue growth
20.8%

Insider activity, last 90 days

Net open-market
$-0.06m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Collaboration and Other Research and Development Revenues Collaboration and other research and development revenues increased by $8.3 million to $11.9 million for the three months ended June 30, 2026 compared to $3.6 million for the same period in 2025. The increase was primarily attributable to recognition of deferred revenue related to the expiration of certain rights to opt-in to additional research programs under our collaboration with BMS. …Editas Medicine, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →